Cholestatic syndromes

Current Opinion in Gastroenterology

Volumn 15, Issue 3, 1999, Pages 217-228

  Trauner, Michael ^a   Boyer, James L ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; BILE DUCT; CHOLESTASIS; FATIGUE; LIVER INJURY; PATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRURITUS; REVIEW;

EID: 0033040892     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199905000-00006     Document Type: Review

References (104)

1. Mueller M, Jansen PLM: The secretory function of the liver: New aspects of hepatobiliary transport. J Hepatol 1998, 28:344-354. Excellent review on hepatobiliary transport systems.
2. Trauner M, Meier PJ, Boyer JL: Molecular pathogenesis of cholestasis. N Engl J Med 1998, 339:1217-1227. This review links the findings from basic research in animal models to cholestatic liver disease in humans.
3. Gerloff T, Stieger B, Hagenbuch B, Madon J, Landmann L, Roth J, et al.: The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 1998, 273:10046-10050. Full-length sequence and function of expression of the BSEP.
4. Strautnieks SS, Bull LN, Knisely AS, Kocoshis SA, Dahl N, et al.: A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 1998, 20:233-238. Important paper on the cloning of the human BSEP and identification of mutations in this gene as a cause of a subtype of PFIC-2.
5. Bouscarel B, Matsuzaki Y, Le M, Gettys TW, Fromm H: Changes in G protein expression account for impaired modulation of hepatic cAMP formation after BDL. Am J Physiol 1998, 274:G1151-G1159.
6. Mukhopadhyay S, Ananthanarayanan M, Stieger B, Meier PJ, Suchy FJ, Anwer MS: Sodium taurocholate cotransporting polypeptide is a serine, threonine phosphoprotein and is dephosporylated by cyclic adenosine monophosphate. Hepatology 1998, 28:1629-1636.
7. Vos TA, Hooiveld GJEJ, Koning H, Childs S, Meijer DKF, Moshage H, et al.: Up-regulation of the multidrug resistance genes, mrp1 and mdr1b, and down-regulation of the organic anion transporter, mrp2, and the bile salt transporter, spgp, in endotoxemic rat liver. Hepatology 1998, 28:1637-1644. This study demonstrates the complexity of the regulation of hepatocellular transport systems in a rat model of endotoxin-induced cholestasis.
8. Trauner M, Arrese M, Lee H, Boyer JL, Karpen SJ: Endotoxin down-regulates hepatic ntcp gene expression via decreased activity of critical transcription factors. J Clin Invest 1998, 101:2092-2100. This study demonstrates transcriptional regulation of a bile salt transporter gene by specific transcription factors in cholestasis.
9. Sun AQ, Ananthanarayanan M, Soroka CJ, Thevananther S, Shneider BJ, Suchy FJ: Sorting of rat liver and ileal sodium-dependent bile acid transporters in polarized epithelial cells. Am J Physiol 1998, 275:G1045-G1055.
10. Bull LN, van Eijk MJT, Pawlikowska L, DeYoung JA, Juijn JA, Liao M, et al.: A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet 1998, 18:219-224. Important study describing the molecular basis of PFIC (Byler disease) and BRIC.
11. Strautnieks SS, Kagalwalla AF, Tanner MS, Knisely AS, Ball L, Freimer N, et al.: Identification of a locus for progressive familial intrahepatic cholestasis PFIC2 on chromosome 2q24. Am J Hum Genet 1997, 61:630-633.
12. de Vree JML, Jacquemin E, Sturm E, Cresteil D, Bosma PJ, Aten J, et al.: Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci U S A 1998, 95:282-287. Description of the molecular basis for a subtype of PFIC (PFIC-3). This study highlights the importance of biliary phospholipids as protective agents against bile duct damage by bile salts.
13. Smith AJ, de Vree JML, Ottenhoff R, Oude Elferink RPJ, SChinkel AH, Borst P: Hepatocyte-specific expression of the human MDR3 P-glycoprotein gene restores the biliary phosphatidylcholine excretion absent in mdr2 (-/-) mice. Hepatology 1998, 28:530-536.
14. Oude Elferink RPJ, Ottenhoff R, van Marle J, Frijters CMG, Smith AJ, Groen AK: Class III P-glycoproteins mediate the formation of lipoprotein X in the mouse. J Clin Invest 1998, 102:1749-1757. This study provides a molecular explanation for the formation of abnormal lipoprotein X in cholestasis.
15. Kozarsky KF, Donahee MH, Rigotti A, Iobal SN, Edelman ER, Krieger M: Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature 1997, 387:414-417.
16. Rigotti A, Trigati BL, Penman M, Rayburn H, Herz J, Krieger M: A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci U S A 1997, 94:12610-12615.
17. Varban ML, Rinninger F, Wang N, Fairchild-Huntress V, Dunmore JH, Fang Q, et al.: Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol. Proc Natl Acad Sci U S A 1998, 95:4619-4624.
18. Strazzabosco M: New insights into cholangiocyte physiology. J Hepatol 1997, 27:945-952.
19. Medina JF, Martinez-Anso E, Vazquez JJ, Prieto J: Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology 1997, 25:12-17. Reduction of AE2 in liver may play a role in the pathogenesis of PBC and is partially reversible under UDCA treatment.
20. Lindblad A, Glaumann H, Strandvik B: A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic-fibrosis-associated liver disease. Hepatology 1998, 27:166-174.
21. +-dependent bile acid transporter in large but not small rat cholangiocytes. Gastroenterology 1997, 113:1734-1740. Important study on the functional and molecular heterogeneity of the bile duct epithelium in regard to bile salt reabsorption.
22. Lazaridis KN, Pham L, Tietz P, Marinelli RA, deGroen PC, Levine S, et al.: Rat cholangiocytes absorb bile acids at their apical domain via the ileal sodium-dependent bile acid transporter. J Clin Invest 1997, 100:2714-2721. Functional evidence for bile salt reabsorption by a cholangiocyte cell line.
23. Li L, Krantz ID, Deng Y, Genin A, Banta AB, Collins CC, et al.: Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat Genet 1997, 16:243-151. One of two papers describing the molecular basis of Alagille syndrome.
24. Oda T, Elkahloun AG, Pike BL, Okajima K, Krantz ID, Genin A, et al.: Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nat Genet 1997, 16:235-242. Second paper describing the molecular basis of Alagille syndrome.
25. Setchell KDR, Schwary M, O'Connell NC, Lund EG, Davis DL, Lathe R, et al.: Identification of a new inborn error in bile acid synthesis: Mutation of the oxysterol 7α-hydroxylase gene causes severe neonatal liver disease. J Clin Invest 1998, 102:1690-1703. Elegant biochemical and molecular characterization of a new inborn bile acid synthesis defect involving the acidic pathway.
26. Rosen H, Reshef A, Maeda N, Lippoldt A, Shpizen S, Triger L, et al.: Markedly reduced bile acid synthesis but maintained levels of cholesterol and vitamin D metabolites in mice with disrupted sterol 27-hydroxylase gene. J Biol Chem 1998, 273:14805-14812.
27. Arnon R, Yoshimura T, Reiss A, Budai K, Lefkowitch JH, Javitt NB: Cholesterol 7α-hydroxylase knockout mouse: A model for monohydroxy bile acid-related neonatal cholestasis. Gastroenterology 1998, 115:1223-1228.
28. Patel T, Roberts LR, Jones BA, Gores GJ: Dysregulation of apoptosis as a mechanism of liver disease: An overview. Semin Liver Dis 1998, 18:105-114.
29. Celli A, Que FG: Dysregulation of apoptosis in the cholangiopathies and cholangiocarcinoma. Semin Liver Dis 1998, 18:177-185. Excellent review on the potential role of apoptosis in the pathogenesis of vanishing bile duct syndromes.
30. Webster CRL, Anwer MS: Cyclic adenosine monophosphate-mediated protection against bile acid-induced apoptosis in cultured rat hepatocytes. Hepatology 1998, 27:1324-1331.
31. Roberts LR, Kurosawa H, Bronk SF, Fesnier PJ, Agellon LB, Leung WY, et al.: Cathepsin B contributes to bile salt-induced apoptosis of rat hepatocytes. Gastroenterology 1997, 113:1714-1726.
32. Faubion WA, Guicciardi ME, Miyoshi H, Bronk SF, Roberts PJ, Svingen PA, et al.: Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest 1999, 103:137-145. Demonstrates the role of Fas receptor pathway with subsequent activation of signaling and effector proteases in bile salt-induced apoptosis.
33. Harada K, Ozaki S, Gershwin ME, Nakanuma Y: Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis. Hepatology 1997, 26:1399-1405.
34. Gapany C, Zhao M, Zimmermann A: The apoptosis protector, bcl-2 protein, is downregulated in bile duct epithelial cells of human liver allografts. J Hepatol 1997, 26:535-542.
35. Celli A, Que FG, Gores GJ, LaRusso NF: Glutathione depletion is associated with decreased Bcl-2 expression and increased apoptosis in cholangiocytes. Am J Physiol 1998, 275:G749-G757.
36. Harnois DM, Que FG, Celli A, LaRusso NF, Gores GJ: Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line. Hepatology 1997, 26:884-890.
37. Chen XM, Levine SA, Tietz P, Krueger E, McNiven MA, Jefferson DM, et al.: Cryptosporidium parvum is cytopathic for cultured human biliary epithelia via an apoptotic mechanism. Hepatology 1998, 28:906-913. An infectious agent mediates bile duct damage by apoptosis.
38. Benz C, Angermueller S, Toex U, Kloeters-Plachy P, Riedel HD, Sauer P, et al.: Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis and cytolysis in rat hepatocytes. J Hepatol 1998, 28:99-106.
39. Rodrigues CMP, Fan G, Ma X, Kren BT, Steer CJ: A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998, 101:2790-2799. This study provides important insights into the antiantiptotic mechanism of UDCA.
40. Lieser MJ, Park J, Natori S, Jones BA, Bronk SF, Gores GJ: Cholestasis confers resistance to the rat liver mitochondrial permeability transition. Gastroenterology 1998, 115:693-701.
41. Koga H, Sakisaka S, Ohishi M, Sata M, Tanikawa K: Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis. Hepatology 1997, 25:1077-1084.
42. Bergasa NV, Schmitt JM, Talbot TL, Alling DW, Swain MG, Turner ML, et al.: Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998, 27:679-684. Demonstrates effectiveness of an oral opiate receptor antagonist in the treatment of pruritus associated with cholestatic liver disease.
43. Wolfhagen FHJ, Sternieri E, Hop WCJ, Vitale G, Bertolotti M, van Buuren HR: Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study. Gastroenterology 1997, 113:1264-1269. First controlled clinical trial demonstrating the effectiveness of an oral opiate receptor antagonist in the treatment of pruritus.
44. Mueller C, Pongratz S, Pidlich J, Penner E, Kaider A, Schemper M, et al.: Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonsit ondansetron: A randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998, 10:865-870.
45. Cauch-Dudek K, Abbey S, Stewart DE, Heathcote EJ: Fatigue in primary biliary cirrhosis. Gut 1998, 42:705-710. Demonstrates the high prevalence of fatigue, sleep disturbances, and depression in patients with PBC.
46. Swain MG, Le T: Chronic cholestasis in rats induces anhedonia and a loss of social interest. Hepatology 1998, 28:6-10.
47. Swain MG, Maric M: Improvement in cholestasis-associated fatigue with a serotonin receptor agonist using a novel rat model of fatigue assessment. Hepatology 1997, 25:291-294.
48. Neuberger J, Thomson R: PBC and AMA: What is the connection. Hepatology 1999, 29:271-276. Excellent review on the role of AMAs in the pathogenesis and clinical course of PBC.
49. Migliaccio C, Nishio A, Van de Water J, Ansari AA, Leung PS, Nakanuma Y, et al.: Monoclonal antibodies to mitochondrial E2 components define autoepitopes in primary biliary cirrhosis. J Immunol 1998, 161:5157-5163.
50. Howard MJ, Fuller C, Broadhurst RW, Perham RN, Tang JG, Quinn J, et al.: Three-dimensional structure of the major autoantigen in primary biliary cirrhosis. Gastroenterology 1998, 115:139-146.
51. Harada K, Van de Water J, Leung PSC, Coppel RL, Nakanuma Y, Gershwin ME: In situ nucleic acid hybridization of pyruvate dehydrogenase complex-E2 in primary biliary cirrhosis: Pyruvate dehydrogenase complex-E2 messenger RNA is expressed in hepatocytes but not in biliary epithelium. Hepatology 1997, 25:27-32.
52. Joplin RE, Wallace LL, Lindsay JG, Palmer JM, Yeaman SJ, Neuberger JM: The human biliary epithelial cell plasma membrane antigen in primary biliary cirrhosis: Pyruvate dehydrogenase X? Gastroenterology 1997, 113:1727-1733.
53. Malmborg AC, Shultz DB, Luton F, Mostov KE, Richly E, Leung PSC, et al.: Penetration and co-localization in MDCK cell mitochondria of IgA derived from patients with primary biliary cirrhosis. J Autoimmun 1998, 11:573-580.
54. Mattalia A, Quaranta S, Leung PSC, Bauducci M, Van de Water J, Calvo PL, et al.: Characterization of antimitochondrial antibodies in healthy adults. Hepatology 1998, 27:656-661.
55. Van Norstrand MD, Malinchoc M, Lindor KD, Therneau TM, Gershwin ME, Leung PSC, et al.: Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: Relationship of levels of autoantibodies to disease progression. Hepatology 1997, 25:6-11.
56. Shimoda S, Van de Water J, Ansari A, Nakamura M, Ishibashi H, Coppel RL, et al.: Identification and precursor frequency analysis of a common T cell epitope motif in mitochondrial autoantigens in primary biliary cirrhosis. J Clin Invest 1998, 15;102:1831-1840. Important study providing evidence for a major role for PDC-E2 in eliciting a B and T-cell response in PBC.
57. Sadamoto T, Joplin R, Keogh A, Mason A, Carman W, Neuberger J: Expression of pyruvate dehydrogenase complex PDC-E2 on biliary cells induced by lymph nodes from primary biliary cirrhosis. Lancet 1998, 352:1595-1596. Preliminary report of a factor isolated from lymph nodes from PBC patients and stimulating expression of mitochondrial antigen (PDC-E2) on cholangiocytes from non-PBC patients.
58. O'Donohue J, Fidler H, Garcia-Barcelo M, Nouri-Aria K, Wiliams R, McFadden J: Mycobacterial DNA not detected in liver sections from patients with primary biliary cirrhosis. J Hepatol 1998, 28:433-438.
59. Mason AL, Xu L, Guo L, Munoz S, Jaspan JB, Bryer-Ash M, et al.: Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet 1998, 351:1620-1624.
60. Kingham JGC, Parker DR: The association between primary biliary cirrhosis and coeliac disease: A study of relative prevalences. Gut 1998, 42:120-122.
61. Niveloni S, Dezi R, Pedreira S, Podesta A, Cabanne A, Vazquez H, et al.: Gluten sensitivity in patients with primary biliary cirrhosis. Am J Gastroenterol 1998, 93:404-408.
62. Feistauer SM, Penner E, Mayr WR, Panzer S: Target platelet antigens of autoantibodies in patients with primary biliary cirrhosis. Hepatology 1997, 25:1343-1345. This study demonstrates that thrombocytopenia in PBC may often be due to immune mechanisms.
63. Fickert P, Trauner M, Sill H, Hinterleitner TA, Stauber RE: Successful steroid treatment of idiopathic thrombocytopenic purpura after orthotopic liver transplantation for primary biliary cirrhosis. Am J Gastroenterol 1998, 10:1985-1986.
64. Jones DEJ, Metcalf JV, Collier JD, Bassendine MF, James OFW: Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 1997, 26:1138-1142.
65. Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R: Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy. Hepatology 1998, 28:296-301. Overlap syndromes between PBC and AIH may be an important cause of resistance to UDCA monotherapy in 9% of patients.
66. Czaja AJ: Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998, 28:360-365.
67. Sherlock S: Autoimmune cholangitis: A unique entity? Mayo Clin Proc 1998, 73:184-190.
68. Pasha T, Heathcote J, Gabriel S, Cauch-Dudek K, Jorgensen R, Therneau T, et al.: Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. Hepatology 1999, 29:21-26. This study demonstrates that UDCA reduces the need for liver transplantation, delays the development of esophageal varices, and saves medical care costs in PBC patients compared with placebo.
69. Bonnand AM, Heathcote EJ, Lindor KD, Poupon RE: Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology 1999, 29:39-43.
70. Gonzalez-Koch A, Brahm J, Antezana C, Smok G, Cumsille MA: The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone. J Hepatol 1997, 27:143-149.
71. Ricci P, Hofmann AF, Hagey LR, Jorgensen RA, Dickson RA, Lindor KD: Adjuvant cholylsarcosine during ursodeoxycholic acid treatment of primary biliary cirrhosis. Dig Dis Sci 1998, 43:1292-1295.
72. Wolfhagen FHJ, van Hoogstraten HJF, van Buuren HR, van Berge-Henegouwen GP, ten Kate FJW, et al.: Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: A 1-year randomized, placebo-controlled study. J Hepatol 1998, 29:736-742.
73. Guanabens N, Pares A, Monegal A, Peris P, Pons F, Alvarez L, et al.: Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: Preliminary results after 2 years. Gastroenterology 1997, 113:219-224.
74. Bergquist A, Glaumann H, Person B, Brome U: Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: A case-control study. Hepatology 1998, 27:311-316. Demonstrates that smoking is a risk factor for cholangiocarcinoma in patients with PSC.
75. Harnois DM, Gores GJ, Ludwig JL, Steers JL, LaRusso NF, Wiesner RH: Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer? J Hepatol 1997, 27:512-516.
76. Keiding S, Hansen SB, Rasmussen HH, Gee A, Kruse A, Roelsgaard K, et al.: Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology 1998, 28:700-706. This study suggests that this new imaging method may be of clinical value for detection of cholangiocarcinoma.
77. Fulcher A, Turner MA, Capps GW, Zfass AM, Baker KM: Half-Fourier RARE MR cholangiopancreatography: Experience in 300 subjects. Radiology 1998, 207:21-32.
78. Kornfeld D, Ekbom A, Ihre T: Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 1997, 41:522-525.
79. Broome U, Chapman RW: Ulcerative colitis: Sclerosing cholangitis today, cancer tomorrow? Gut 1997, 41:571-572. Excellent editorial reviewing the potential association between PSC and colorectal cancer in ulcerative colitis.
80. Nuako KW, Ahlquist DA, Sandborn WJ, Mahoney DW, Siems DM, Zinsmeister AR: Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis. Cancer 1998, 82:822-826.
81. Loftus EV, Aguilar HI, Sandborn WJ, Tremaine WJ, Krom RAF, Zinsmeister AR, et al.: Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology 1998, 27:685-690.
82. McNair ANB, Moloney M, Portmann BC, Williams R, MacFarlane IG: Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol 1998, 93:777-784. Five cases highlighting the clinical relevance of overlap syndromes between PSC and AIH.
83. Luketic VAC, Gomez DA, Sanyal AJ, Shiffman MLL: An atypical presentation for primary sclerosing cholangitis. Dig Dis Sci 1997, 2009-2016.
84. Angulo P, Therneau TM, Jorgensen RA, DeSotel CK, Egan KS, Dickson ER, et al.: Bone disease in patients with primary sclerosing cholangitis: Prevalence, severity and prediction of progression. J Hepatol 1998, 29:729-735.
85. Bacq Y, Sapey T, Brechot MC, Pierre F, Fignon A, Dubois F: Intrahepatic cholestasis of pregnancy: A French prospective study. Hepatology 1997, 26:358-364. This study suggests a role for oral progesterone in triggering ICP.
86. Serrano MA, Brites D, Larena MG, Monte MJ, Bravo MP, Oliveira N, Marin JJG: Beneficial effect of ursodeoxycholic acid on alterations induced by cholestasis of pregnancy in bile acid transport across the human placenta. J Hepatol 1998, 28:829-839.
87. Meng LJ, Reyes H, Palma J, Hernandez I, Ribalta J, Sjoevall J: Profiles of bile acids and progesterone metabolites in the urine and serum of women with intrahepatic cholestasis of pregnancy. J Hepatol 1997, 27:346-357.
88. Meng LJ, Reyes H, Palma J, Hernandez I, Ribalta J, Sjoevall J: Effects of ursodeoxycholic acid on conjugated bile acids and progesterone metabolites in serum and urine of patients with intrahepatic cholestasis of pregnancy. J Hepatol 1997, 27:1029-1040.
89. Brites D, Rodrigues CMP, Oliveira N, da Canceicao Cardoso M, Graca LM: Correction of maternal serum bile acid profile during ursodeoxycholic acid therapy in cholestasis of pregnancy. J Hepatol 1998, 28:91-98.
90. Palma J, Reyes H, Ribalta J, Hernandez I, Sandoval L, Almuna R, et al.: Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: A randomized, double-blind study controlled with placebo. J Hepatol 1997, 27:1022-1028. First controlled trial demonstrating that UDCA improves cholestasis of pregnancy and may improve fetal outcome.
91. Leevy CB, Koneru B, Klein KM: Recurrent familial prolonged intrahepatic cholestasis of pregnancy associated with chronic liver disease. Gastroenterology 1997, 113:966-972.
92. Sanchez-Campos S, Lopez-Acebo R, Gonzalez P, Culebras JM, Tunon MJ, Gonzalez-Gallego J: Cholestasis and alterations of glutathione metabolism induced by tacrolimus (FK506) in the rat. Transplantation 1998, 66:84-88.
93. Moran D, Gonzalez De Buitrago JM, Fernandez E, Galan AI, Munoz ME, Jimenez R: Inhibition of biliary glutathione secretion by cyclosporine A in the rat: Possible mechanisms and role in the cholestasis induced by the drug. J Hepatol 1998, 29:68-77.
94. Chan FKL, Zhang Y, Lee SS, Shaffer EA: The effects of liver transplantation and cyclosporine on bile formation and lipid composition: An experimental study in the rat. J Hepatol 1998, 28:329-336.
95. Shen J, Moy JA, Green MD, Guengerich FP, Baron J: Immunohistochemical demonstration of β-naphthoflavone-inducible cytochrome P450 1A1/1A2 in rat intrahepatic biliary epithelial cells. Hepatology 1998, 27:1483-1491.
96. Van Steenbergen W, Peeters P, De Bondt J, Staessen D, Buescher H, Laporta T, et al.: Nimesulide-induced acute hepatitis: Evidence from six cases. J Hepatol 1998, 29:135-141.
97. Tamm M, Sieber C, Schnyder F, Haefeli WE: Moxonidine-induced cholestatic hepatitis. Lancet 1997, 350:1822.
98. Srivastava M, Perez-Atayde, Jonas MM: Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child. Gastroenterology 1998, 115:743-746.
99. Fernandes NF, Geller SA, Fong TL: Terbinafine hepatotoxicity: A case report and review of the literature. Am J Gastroenterol 1998, 93:459-460.
100. Mallat A, Zafrani ES, Metreau JM, Dhumeaux D: Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts. Dig Dis Sci 1997, 42:1486-1488.
101. Koeppel TA, Trauner M, Mennone A, Arrese M, Rios-Verez L, Boyer JL: Role of glutathione in hepatic bile formation during reperfusion after cold ischemia of the rat liver. J Hepatol 1998, 28:812-819.
102. Lenzen R, Elster J, Behrend C, Hampel KE, Bechstein WO, Neuhaus P: Bile acid-independent bile flow is differently regulated by glucagon and secretin in humans after orthotopic liver transplantation. Hepatology 1997, 26:1272-1281.
103. Chan TM, Wu PC, Li FK, Lai CL, Cheng IKP, Lai KN: Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology 1998, 115:177-181.
104. Moreno A, Carreno V, Cano A, Gonzalez C: Idiopathic biliary ductopenia in adults without symptoms of liver disease. N Engl J Med 1997, 336:835-838. Elevations in serum γ-GT may reflect asymptomatic cases of biliary ductopenia.